Dara Biosciences (DARA) 0.88 $DARA DARA BioSciences wins

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2016 at 1:02 AM

Dara Biosciences (DARA) 0.88 $DARA

DARA BioSciences wins stockholder's approval of merger with and into Midatech
M2 - Thu Dec 03, 5:27AM CST
DARA BioSciences (NasdaqCM

ARA) reported on Wednesday the receipt of stockholders' approval for the adoption of the merger agreement by and among DARA, Midatech Pharma PLC (Midatech) and certain other parties thereto.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Stockholder Approval of Merger With Midatech
Marketwired - Wed Dec 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that its stockholders have approved the adoption of the previously announced merger agreement by and among DARA, Midatech Pharma PLC ("Midatech"

and certain other parties thereto.
DARA: 0.88 (-0.06)

DARA BioSciences posts higher loss of USD2.7m for Q3 2015
M2 - Tue Nov 03, 4:21AM CST
Pharmaceutical company DARA BioSciences (NasdaqCM

ARA) disclosed on Monday that it recorded a loss attributable to controlling interest of approximately USD2.7m (USD0.14 per share) for the third quarter ended 30 September 2015.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Third Quarter 2015 Results
Marketwired - Mon Nov 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2015 results.
DARA: 0.88 (-0.06)

DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015
Marketwired - Tue Oct 06, 7:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA) today announced that it will be featured as a presenting company at the 2015 Aegis Growth Conference, sponsored by Aegis Capital Corp. The Aegis Growth Conference, which will feature growth companies in Healthcare, Technology, Telecom and Aerospace-Defense sectors, will be held October 7-9, 2015 at The Encore at Wynn Hotel in Las Vegas, NV. DARA BioSciences is an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment.
DARA: 0.88 (-0.06)

DARA BioSciences unveils Oravig (miconazole) in the oncology and primary care markets in the US for treatment of adults with oral thrush
M2 - Tue Oct 06, 4:36AM CDT
Specialist pharmaceutical company DARA BioSciences (NasdaqCM

ARA) reported on Monday the availability of Oravig, the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush, into the oncology and primary care markets in the US.
DARA: 0.88 (-0.06)

DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush
Marketwired - Mon Oct 05, 7:01AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced today the U.S. launch of Oravig -- the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush -- into the Oncology and Primary Care markets. Beginning this week, DARA and its marketing partner Mission Pharmacal Company, a privately held pharmaceutical company based in San Antonio, TX, will simultaneously begin promotion of Oravig with two separate sales forces focusing on the highest prescribing physicians of oral thrush therapy; DARA will promote Oravig exclusively in Oncology with its 20 person nationwide sales force and Mission will utilize its 40 person-strong sales team to promote the product exclusively to the Primary Care market. DARA was granted exclusive U.S. rights to Oravig in March 2015, under a Commercialization Agreement with Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs.
DARA: 0.88 (-0.06)

DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
Marketwired - Wed Sep 23, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Ladenburg Thalmann 2015 Healthcare conference. The conference is being held September 29, 2015, at the Sofitel Hotel in New York City.
DARA: 0.88 (-0.06)

DARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 9, 2015
Marketwired - Wed Sep 02, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Rodman and Renshaw Global Investment Conference. The conference is being held September 8-10, 2015, at the Saint Regis Hotel in New York City.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Second Quarter 2015 Results
Marketwired - Wed Aug 12, 3:15PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2015 results.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2015 Results
Marketwired - Mon Aug 10, 7:00AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the second quarter ended June 30, 2015, after the close of the market on Wednesday, August 12, 2015.
DARA: 0.88 (-0.06)

Robbins Arroyo LLP: Acquisition of DARA BioSciences, Inc. (DARA) by Midatech Pharma Plc (MTPH) May Not Be in Shareholders' Best Interests
PR Newswire - Thu Jun 25, 2:49PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of DARA BioSciences Inc. (NASDAQ: DARA) by Midatech Pharma Plc (London: MTPH). On June 4, 2015, the two companies announced the signing of a definitive merger agreement pursuant to which Midatech will acquire DARA. Under the terms of the agreement, DARA shareholders will receive 0.272 shares of Midatech for each share of DARA they own, the value of which is equivalent to $1.20 per share of DARA common stock.
DARA: 0.88 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NACD Honors Top Board Leaders with 2026 Awards

Celebrating Boardroom Mavericks at NACD Gala September 2026 has brought some sparkling recognition to the elites guiding today's corporate governance landscapes. The National Association of Corporate Directors (NACD) has announced their Directorship 100 honorees, tipping their hats to stellar individuals firing on all cylinders in the boardroom. Who's Getting the Nod?...

Anixa Expands Global Footprint with Aussie Patent

Breaking New Ground in Cancer Immunotherapy Today feels like a pivotal day for Anixa Biosciences. Their announcement about securing a patent in Australia for their trailblazing breast cancer vaccine is like planting a flag on new, promising territory. This is no minor step; it's a strategic leap for the company as it strengthens its intellectual grip on the global...

Nature-Based Solutions: The Economic And Community Impact

Harnessing Nature to Boost Economies You ever stop to think about how nature itself might just be the best investment? Well, the Walton Family Foundation surely does, betting big on nature-based solutions. Their latest initiative, 'Human Nature,' is shedding light on how these solutions aren't just saving ecosystems — they're fortifying economies and enriching...

U.N. Leaders Converge at NYSE, Forus Soars to $3B Valuation

A Busy Morning at the NYSE with Key Guests and Global Events In a world where high-stakes diplomacy and roaring market bells go hand in hand, today brings the U.S. Secretary of State, Marco Rubio, to the New York Stock Exchange. With the 81st Session of the United Nations General Assembly shaking up the Big Apple, the city finds itself at the intersection of politics and...

Molex's VersaBeam Mini Pushes AI Data Center Limits

Game-Changer for AI Data Centers? Across the tech landscape, space is a premium, and Molex's new VersaBeam Mini arrives like a hail Mary in the fourth quarter. In AI data centers, squeezing down every single component counts—especially when optical density's in play. What we're seeing here is a potential paradigm shift. A 3x density improvement from a tiny 3.5 x 9 mm...

Lititz Mutual Embraces AI with Guidewire ProNavigator

It's not every day you see a company like Lititz Mutual making moves in the artificial intelligence (AI) arena. Based out of Lititz, Pennsylvania, this insurance firm has decided to shake things up with Guidewire's ProNavigator AI assistant. Forging New Paths in Insurance Lititz Mutual is set to inject some serious tech into their operations. The goal? Make life easier...

Castillo Engineering Gears Up with New VP Appointments

New Leadership to Drive Expansion In a boost to its commitment to scaling up, Castillo Engineering, based in Maitland, Florida, has roped in two veterans from the renewables sector as vice presidents. Aaron Carrillo and Devin Radovich, who share a history of successful collaboration at Renewable Energy Systems Americas (RES), are set to guide Castillo's growth in the...

Lawsuit Targets Electrical Consultants' Labor Practices

Trouble Brews at Electrical Consultants, Inc. Right on the heels of a long workday, some employees of Electrical Consultants, Inc. seem to be getting a double whammy. The company is tangled up in a class action lawsuit lodged by the well-known Blumenthal Nordrehaug Bhowmik De Blouw LLP. This ain't your everyday grievance, folks; we're talking meal and rest period...

Navigating AI's New Era: Dresner's 2026 Findings

Big Insights in the AI World of 2026 Well folks, if there's one thing making waves in the boardrooms this year, it's AI. Dresner Advisory Services just threw down a gauntlet for companies with their fresh batch of reports focused on the dizzying world of AI. They ripped right into it, exploring how firms can bag a heap of benefits and deal with the hurdles that come with...

Lavior and CR Fitness Team for Wellness Reach

Botanical Care Meets Gym Life in the Southeast Lavior, the botanical whiz kids of wound and skin care out of Miami, are shaking hands with CR Fitness, Crunch's big-time franchise operator carrying the flag across the Southeast. They’ve ironed out a deal that’ll park Lavior’s products in more than 60 gyms covering Florida, Georgia, North Carolina, and Texas. It’s a...